rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

CONMED Corporation

CNMD · NYSE

Health CareMedical DevicesLeading

CNMD stood above a rising 150-day average in 12 of the last 52 weekly readings, including each of the last 12 weeks. It is 14.4% above that average now. Medical Devices: 29% of its 181 stocks in an uptrend (−4 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
12 in a row
Industry in uptrend
29% -4 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$161K
Officials’ trades on record
6
Institutions holding
226 (+13)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 12 of 52 weeks.

22 Apr – 21 Oct
15%27%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$220K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

6 disclosed lines: House 2, Senate 0, executive 4; 2 people.

WhoDidAmountTraded
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k8 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$15k–$50k4 Jun 2026filed 22 Aug 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k30 Apr 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$15k–$50k26 Jan 2026filed 14 May 2026
Van Taylor House: U.S. House ClerkTX03sold$1k–$15k25 Mar 2019filed 15 Apr 2019
Van Taylor House: U.S. House ClerkTX03bought$1k–$15k15 Feb 2019filed 14 Mar 2019

Insiders

Buy orders, 12 months0
Sale orders, 12 months2
Buyers · sellers0 · 2

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders226+13 on the quarter
New · exited42 · 29
Reported value$1.1B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.reduced · filed 7 Aug 20264,820,739$157.8M-4,434−0.1%
EARNEST PARTNERS LLCreduced · filed 13 Aug 20262,505,295$82.0M-64,358−2.5%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20262,188,761$71.6M+112,344+5.4%
FULLER & THALER ASSET MANAGEMENT, INC.reduced · filed 12 Aug 20261,579,917$51.7M-61,849−3.8%
STATE STREET CORPadded · filed 7 Aug 20261,417,468$46.4M+33,450+2.4%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20261,355,728$44.4M-28,314−2.0%
BANK OF AMERICA CORPreduced · filed 14 Aug 20261,341,409$43.9M-61,211−4.4%
DIMENSIONAL FUND ADVISORS LPreduced · filed 11 Aug 20261,317,370$43.1M-75,550−5.4%
SEI INVESTMENTS COreduced · filed 14 Aug 2026988,151$32.3M-16,564−1.6%
Invenomic Capital Management LPreduced · filed 14 Aug 2026842,162$27.6M-92,439−9.9%
31 Mar 2023 – 30 Jun 2026
187223259Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Kim Kelderman Company insiderDirector · last 8 Sep 20260 · 0
John E. Gallagher Company insiderExecutive Vice President & CFO · last 15 Jul 20260 · 0
Donald J. Trump Executive branchWhite House Office · last 8 Jul 20262 · 2
Celine Christine Martin Company insiderDirector · last 1 Jul 20260 · 0
Jeffrey B. Mirviss Company insiderDirector · last 1 Jul 20260 · 0
Barbara J. Schwarzentraub Company insiderDirector · last 2 Jun 20261 · 1
Charles Farkas Company insiderDirector · last 2 Jun 202612 · 2
David M. Bronson Company insiderDirector · last 2 Jun 20262 · 0
LaVerne H. Council Company insiderDirector · last 2 Jun 20260 · 0
Mark Kaye Company insiderDirector · last 2 Jun 20260 · 0
Pat Beyer Company insiderPresident & CEO · last 1 Apr 20262 · 2
Brent Lalomia Company insiderExecutive VP RA, QA · last 6 Mar 20260 · 0

Same industry

RCEL Avita MedicalLeading+127%
HTFL HeartflowLeading+59%
ATRC AtriCureLeading+51%
HAE HaemoneticsLeading+44%
BVS BioventusLeading+24%

Distance from each stock’s own 150-day average.

Government contracts

Awards1
Total$15K
Latest13 Oct 2026

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202554.6%
Operating profit marginFY 2025 · to 31 Dec 20257.5%
Free cash flow marginFY 2025 · to 31 Dec 202511.0%
Return on capital employedFY 2025 · to 31 Dec 20255.1%
Cash conversionFY 2025 · to 31 Dec 2025363%
Interest coverFY 2025 · to 31 Dec 20253.30×
Research spendFY 2025 · to 31 Dec 20254.1%
Share count trendFY 2025 · to 11 Feb 2026-1.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$40.8M
Free cash flowFY 2025 · to 31 Dec 2025$150.9M

Analyst forecasts

No analyst forecasts yet.